Compare New York Times Co (NYT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Twist Bioscience Corp — how do they compare? New York Times Co trades at $66.6 (market cap $10.74B), while Twist Bioscience Corp trades at $125.52 (market cap $8.26B). The key difference: New York Times Co is the larger of the two by market cap, and New York Times Co pays a 1.38% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| NYT | TWST | |
|---|---|---|
Market Cap | $10.74B | $8.26B |
Sector | Media | Health |
52-Week High | $85.86 | $153.10 |
52-Week Low | $54.66 | $24.16 |
Enterprise Value | $10.14B | $8.18B |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $67.96, up 1.01% today, with a neutral technical signal. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight strong operational performance, supported by rising revenue and net income margins. The stock's valuation metrics include a P/E of 28.32 and P/S of 3.75, while positive cash flow trends and a dividend payment reflect financial stability.
Outlook remains cautiously optimistic with a consensus price target of $76.00, offering potential upside. Key risks include ongoing legal challenges with OpenAI over copyright issues and competitive pressures in digital media. Institutional interest is evident, but regulatory and market sentiment uncertainties warrant monitoring for sustained growth.
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
